Protective effect of endotoxin instillation on subsequent bacteria-induced acute lung injury in rats.
The phagocytic capability afforded by neutrophil influx into the lungs is essential to ward off invading bacteria. The objective of this study was to evaluate the effect of prior neutrophil recruitment induced by alveolar instillation of endotoxin (LPS, 200 micrograms/kg) 16 h before a pulmonary infection caused by instillation of live Pseudomonas aeruginosa ([PYO]: 1.5 x 10(8) colony-forming units [cfu]/kg) in rats. A first series of experiments showed that lipopolysaccharide (LPS) instillation induced recruitment of alveolar neutrophils that were capable, ex vivo, of elastase exocytosis, reactive oxygen species secretion, and PYO killing. In a second set of experiments, LPS followed by PYO was compared with PYO alone (n = 11 surviving rats in each group). Parameters were studied 24 h after the bacterial challenge. As compared with PYO alone, pretreatment with LPS followed by PYO was associated with decreased mortality (0% versus 54%, p < 0.05), decreased protein leakage into bronchoalveolar lavage (BAL) fluid (1.8 +/- 0.4 versus 13.5 +/- 2.2 mg/ml, p < 0.001), and improved bacterial clearance from BAL (4.0 +/- 1.4 x 10(2) versus 1.2 +/- 0.5 x 10(4) cfu/ml, p < 0.05) and from pulmonary parenchyma (8.5 +/- 6.4 x 10(5) versus 1.9 +/- 0.8 x 10(7) cfu/ml, p < 0.05). We conclude that prior alveolar endotoxin instillation induces local recruitment of functionally active neutrophils, and that this is associated with resistance to subsequent experimental pneumonia.
Jean
D
D
Institut National de la Santé et de la Recherche Médicale, INSERM U 296, France.
Rezaiguia-Delclaux
S
S
Delacourt
C
C
Leclercq
R
R
Lafuma
C
C
Brun-Buisson
C
C
Harf
A
A
Delclaux
C
C
D000818:Animals; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000382:microbiology; D002634:Chemotaxis, Leukocyte / Q000502:physiology; D015169:Colony Count, Microbial; D004731:Endotoxins / Q000008:administration & dosage / Q000494:pharmacology*; D005089:Exocytosis / Q000502:physiology; D007958:Leukocyte Count; D019272:Leukocyte Elastase / Q000378:metabolism; D008070:Lipopolysaccharides / Q000008:administration & dosage / Q000494:pharmacology; D008168:Lung / Q000382:microbiology / Q000473:pathology; D008297:Male; D018375:Neutrophil Activation / Q000502:physiology; D009504:Neutrophils / Q000502:physiology; D010587:Phagocytosis / Q000502:physiology; D018410:Pneumonia, Bacterial / Q000503:physiopathology / Q000517:prevention & control; D011506:Proteins / Q000032:analysis; D011552:Pseudomonas Infections / Q000473:pathology / Q000503:physiopathology*; D011550:Pseudomonas aeruginosa / Q000254:growth & development / Q000502:physiology*; D011650:Pulmonary Alveoli / Q000382:microbiology / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017382:Reactive Oxygen Species / Q000378:metabolism; D012128:Respiratory Distress Syndrome / Q000382:microbiology*; D015996:Survival Rate
D004731:Endotoxins; D008070:Lipopolysaccharides; D011506:Proteins; D017382:Reactive Oxygen Species; D019272:Leukocyte Elastase